FDA Approves PERJETA — Genentech, Inc.

# FDA Approves Genentech's PERJETA (Pertuzumab) for HER2-Positive Breast Cancer Genentech, Inc. has received FDA approval for PERJETA (pertuzumab), a novel HER2-targeted therapy administered intravenously, positioning the company to capture significant market share in the oncology space and potentially generating billions in annual revenue from the large population of HER2-positive breast cancer patients. The approval strengthens Genentech's breast cancer portfolio and establishes a new treatment paradigm that could reshape competitive dynamics in the targeted